18645-88-0

Basic information

• Product Name: 2,3-DIAMINOFLUOROBENZENE
• Synonyms: 2-amino-3-fluorophenylamine;3-Fluorobenzene-1,2-diamine;3-Fluorobenzene-1,2-diamine 97%;2,3-Diaminofluorobenzene, 3-Fluorophenylene-1,2-diamine;3-Fluoro-1,2-phenylenediaMine;1,2-DiaMino-3-fluorobenzene;3-Fluorophenylene-1,2-diamine, 1,2-Diamino-3-fluorobenzene;1,2-DiaMino-3-fluorobenzene[2,3-DiaMinofluorobenzene]
• CAS NO: 18645-88-0
• Molecular Formula: C₆H₇FN₂
• Molecular Weight: 126.13
• Product Categories: Amines;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 18645-88-0.mol

Chemical Properties

• Melting Point: 40.9°C-42.2°C
• Boiling Point: 242 °C at 760mmHg
• Flash Point: 105.6 °C
• Appearance: /
• Density: 1.284 g/cm³
• Vapor Pressure: 0.0348mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.15±0.10(Predicted)
• Sensitive: Light Sensitive/Air Sensitive
• CAS DataBase Reference: 2,3-DIAMINOFLUOROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIAMINOFLUOROBENZENE(18645-88-0)
• EPA Substance Registry System: 2,3-DIAMINOFLUOROBENZENE(18645-88-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 18645-88-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
2,3-Diaminofluorobenzene is used as a building block in the chemical synthesis industry for the production of various organic compounds. Its aromatic and amine-like properties make it a valuable component in the creation of dyes, pharmaceuticals, and agrochemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2,3-diaminofluorobenzene is used as a precursor in the synthesis of various medicinal compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
2,3-Diaminofluorobenzene is also utilized in the agrochemical industry for the development of new pesticides and other agricultural chemicals, contributing to more effective crop protection strategies.
Used in Dye Production:
2,3-DIAMINOFLUOROBENZENE is used as a key intermediate in the production of dyes, particularly fluorescent dyes, which have applications in various industries, including textiles, plastics, and printing.
Used in Biological Imaging:
2,3-Diaminofluorobenzene serves as a precursor in the synthesis of imaging agents for biological applications, where fluorescent dyes are essential for visualizing cellular structures and processes in research and diagnostics.
Safety and Handling:
It is crucial to handle 2,3-diaminofluorobenzene with care, as it can pose hazards to human health and the environment if not managed properly. Appropriate safety measures should be taken during its production, use, and disposal to minimize potential risks.

InChI:InChI=1/C6H7FN2/c7-4-2-1-3-5(8)6(4)9/h1-3H,8-9H2

Upstream product

• 348-54-9 2-Fluoroaniline 
• 19064-24-5 2,6-difluoro-1-nitrobenzene 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 372-19-0 meta-fluoroaniline 
• 342-52-9 N-(2-fluoro-6-nitrophenyl)acetamide 
• 399-31-5 N-(2-fluorophenyl)acetamide 
• 17809-36-8 2-fluoro-6-nitroaniline 

Downstream Products

• 121712-03-6 4-fluorobenzimidazolyl-2-thione 
• 55687-17-7 8-fluoro-2(1H)-quinoxalinone 
• 55687-16-6 5-fluoro-2(1H)-quinoxalinone 
• 121712-06-9 2,3-dihydro-8-fluorothiazolo<3,2a>benzimidazole 
• 406945-10-6 5-fluoro-1-isopropenyl-1,3-dihydro-benzoimidazol-2-one 
• 40644-14-2 5-iodo-1,3-dihydro-2H-1,3-benzimidazol-2-one 
• 256519-10-5 4-fluoro-1,3-dihydro-2H-1,3-benzimidazole-2-one 
• 1417898-53-3 7-fluoro-4-N,N-dimethylaminosulfonyl-2,1,3-benzothiadiazole 
• 1427029-26-2 1-(2-chlorophenyl)-6-fluoro-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline 
• 1426821-96-6 1-(2-chlorophenyl)-9-fluoro-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline 
• 1064137-04-7 2-(bromomethyl)-3-(2-chlorophenyl)-5-fluoroquinoxaline 
• 1064137-02-5 3-(bromomethyl)-2-(2-chlorophenyl)-5-fluoroquinoxaline 
• 394223-23-5 (4-Fluoro-1H-benzimidazol-2-yl)-methylamine 

Relevant articles and documents

Regioselective Radical Arene Amination for the Concise Synthesis ofortho-Phenylenediamines

The formation of arene C-N bonds directly from C-H bonds is of great importance and there has been rapid recent development of methods for achieving this through radical mechanisms, often involving reactiveN-centered radicals. A major challenge associated with these advances is that of regiocontrol, with mixtures of regioisomeric products obtained in most protocols, limiting broader utility. We have designed a system that utilizes attractive noncovalent interactions between an anionic substrate and an incoming radical cation in order to guide the latter to the areneorthoposition. The anionic substrate takes the form of a sulfamate-protected aniline and telescoped cleavage of the sulfamate group after amination leads directly toortho-phenylenediamines, key building blocks for a range of medicinally relevant diazoles. Our method can deliver both free amines and monoalkyl amines allowing access to unsymmetrical, selectively monoalkylated benzimidazoles and benzotriazoles. As well as providing concise access to valuableortho-phenylenediamines, this work demonstrates the potential for utilizing noncovalent interactions to control positional selectivity in radical reactions.

Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators

Recent studies examined the possibility to overcome imatinib resistance in chronic myeloid leukemia (CML) patients by combination therapy with peroxisome proliferator-activated receptor gamma (PPARγ) ligands. Pioglitazone, a full PPARγ agonist, improved the survival of patients by the gradual elimination of the residual CML stem cell pool. To evaluate the importance of the pharmacological profile of PPARγ agonists on the ability to circumvent resistance, the partial PPARγ agonist 4‘-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1’-biphenyl]-2-carboxylic acid, derived from telmisartan, and other related derivatives were investigated. The 4-substituted benzimidazole derivatives bearing a [1,1′-biphenyl]-2-carboxamide moiety sensitized K562-resistant cells to imatinib treatment. Especially the derivatives 18a-f, which did not activate PPARγ to more than 40% at 10 μM, retrieved the cytotoxicity of imatinib in these cells. The cell death modulating properties were higher than that of pioglitazone. It is of interest to note that all novel compounds were not cytotoxic neither on non-resistant nor on resistant cells. They exerted antitumor potency only in combination with imatinib.

FERROPORTIN INHIBITORS AND METHODS OF USE

The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis.

Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase

A number of new F-triazolequinolones (FTQs) and alkoxy-triazolequinolones (ATQs) were designed, synthesized and evaluated for their activity against Mycobacterium tuberculosis H37Rv. Five out of 21 compounds exhibited interesting minimum inhibitory concen

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors

A series of 2-aminopyrimidine derivatives were designed and synthesized as highly selective FGFR4 inhibitors. One of the most promising compounds 2n tightly bound FGFR4 with a Kd value of 3.3 nM and potently inhibited its enzymatic activity with an IC50 value of 2.6 nM, but completely spared FGFR1/2/3. The compound selectively suppressed proliferation of breast cancer cells harboring dysregulated FGFR4 signaling with an IC50 value of 0.38 μM. Furthermore, 2n exhibited extraordinary target specificity in a Kinome-wide screen against 468 kinases, with S(35) and S(10) selectivity scores of 0.01 and 0.007 at 1.0 μM, respectively.

Fluorinated Fe(III) salophene complexes: Optimization of tumor cell specific activity and utilization of fluorine labeling for in vitro analysis

Fluorine-substituted iron(III) salophene complexes (salophene = N,N'-bis(salicylidene)-1,2-phenylenediamine) were synthesized and evaluated for biological activity. All complexes showed growth inhibitory effects with IC50 values ranging from 0.

SUBSTITUTED TRIAZOLOPYRAZINES AND USES THEREOF

The present invention is directed to substituted triazolopyrazine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psychiatric disorders.

TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS

The present invention is directed to triazolopyrazine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psychiatric disorders.

New fluorogenic benzothiadiazole and benzoselenadiazole reagents to yield environment-sensitive fluorophores via a reaction with amines

We introduce 7-fluoro-4-N,N-dimethylaminosulfonyl-2,1,3-benzothiadiazole and 7-fluoro-4-N,N-dimethylaminosulfonyl-2,1,3-benzoselenadiazole as new fluorogenic reagents for amines. These reagents are nonfluorescent themselves and can easily react with nonfl

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.